** Shares of vaccine developer HilleVax rise ~14% to $2.13 premarket
** HLVX to lay of about 28 employees, or about 70% of its workforce, to reduce operating costs, co said on Thursday
** Co says remaining team will focus on developing norovirus vaccine candidates, HIL-214 and HIL-216
** Co estimates that it will incur charges associated with the workforce reduction of about $6.1 mln
** As of Dec. 31, 2023, HLVX had 90 full-time employees - SEC filling
** Earlier this year, HLVX laid off about 41 employees
** As of last close, stock has fallen 88.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。